Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester,Issue Date
2019
Metadata
Show full item recordCitation
Adderley H, Ackermann CJ, Califano R. Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? Annals of Translational Medicine. 2019;7(S8):S346-S.Journal
Annals of Translational MedicineDOI
10.21037/atm.2019.09.116Additional Links
https://dx.doi.org/10.21037/atm.2019.09.116Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/atm.2019.09.116